Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.
Charli E HarlowVickas V PatelDawn M WaterworthAndrew R WoodRobin N BeaumontKatherine S RuthJessica TyrrellAsami Oguro-AndoAudrey Y ChuTimothy M FraylingPublished in: Human molecular genetics (2022)
These findings suggest that long-term alterations in Hgb through PHD inhibition are unlikely to substantially increase cardiovascular disease risk; using large disease GWAS data, we could exclude odds ratios of 1.35 of cardiovascular risk for a 1.00 g/dL increase in Hgb.